Urologia internationalis
Extended versus Standard Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer: A Real-World Cohort Study.
Can Aydogdu, Florian Urban, Elena Berg, Melanie Götz, Severin Rodler, Isabel Brinkmann, Benazir Enzinger, Marie Semmler, Frederik Kolligs, Marina Hoffmann, Leo F Stadelmeier, Thilo Westhofen, Lena M Unterrainer, Volker Heinemann, Christian G Stief
Published: 202610.1159/000550580
Abstract
BACKGROUND: Androgen deprivation therapy (ADT) plus six cycles of docetaxel was the global first-line standard for metastatic hormone-sensitive prostate cancer (mHSPC) before triplet regimens emerged. In many regions, this approach remains the only a…
Preview only. Read the full abstract at the source